---
schema_version: "secwatch.filing_event.v1"
accession: "0001127537-24-000013"
form_type: "8-K"
ticker: "LUNG"
cik: "0001127537"
company_name: "Pulmonx Corp"
filed_at: "2024-02-21T23:59:59+00:00"
generated_at: "2026-06-05T21:42:19.785264+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Pulmonx Q4 revenue $19.3M (+25% YoY); full-year 2023 revenue $68.7M (+28% YoY)

## Summary
- Record Q4 U.S. revenue of $13.7M (+45% YoY); added 14 new Zephyr Valve treatment centers.
- Gross margin improved to 75% in Q4; full-year gross margin flat at 74%.
- Net loss of $13.9M ($0.36/share) in Q4; full-year net loss $60.8M ($1.60/share).
- Adjusted EBITDA loss narrowed to $39.0M in 2023 from $41.1M in 2022.
- 2024 revenue guidance of $81-84M; expects gross margin 74-75% and OpEx $132-134M.

## SEC filing metadata
- accession: 0001127537-24-000013
- form_type: 8-K
- ticker: LUNG
- cik: 0001127537
- company_name: Pulmonx Corp
- filed_at: 2024-02-21T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1127537/000112753724000013/0001127537-24-000013-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1127537/000112753724000013/lung-20240221.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001127537-24-000013
- JSON: https://secwatch.observer/filing/0001127537-24-000013.json
- Plain text: https://secwatch.observer/filing/0001127537-24-000013.txt

## Key facts
- Earnings Releases
  Pulmonx Corp reported fourth quarter ended December 31, 2023 results: revenue $19.3 million, net income $13.9 million net loss, EPS -$0.36 per share.
  - Period: fourth quarter ended December 31, 2023
  - Revenue: $19.3 million
  - Net income: $13.9 million net loss
  - EPS: -$0.36 per share
  - Result: reported results
  source text: Total worldwide revenue in the fourth quarter of 2023 was $19.3 million, a 25% increase from $15.4 million in the fourth quarter of 2022 and an increase of 23% on a constant currency basis.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1127537/000112753724000013/0001127537-24-000013-index.htm
- Earnings Releases
  Pulmonx Corp reported full year 2024 results: revenue $81 million to $84 million. Guidance initiated.
  - Period: full year 2024
  - Revenue: $81 million to $84 million
  - Guidance: initiated
  - Result: guidance update
  source text: Pulmonx expects revenue for the full year 2024 to be in the range of $81 million to $84 million.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1127537/000112753724000013/0001127537-24-000013-index.htm
- Earnings Releases
  Pulmonx Corp reported full year ended December 31, 2023 results: revenue $68.7 million, net income $60.8 million net loss, EPS -$1.60 per share.
  - Period: full year ended December 31, 2023
  - Revenue: $68.7 million
  - Net income: $60.8 million net loss
  - EPS: -$1.60 per share
  - Result: reported results
  source text: Total worldwide revenue for the full year of 2023 was $68.7 million, a 28% increase from $53.7 million for the full year of 2022 and an increase of 28% on a constant currency basis.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1127537/000112753724000013/0001127537-24-000013-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.